FDA eyes pharmacogenomics data. by Wakefield, Julie
When we try to pick out anything by itself, we find it hitched to 
everything else in the universe.
John Muir
My First Summer in the Sierra (1911) 
Environews Forum
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Silent Advances 
A growing body of research shows that
gene silencing is a critical component of
many diseases. In particular, scientists con-
tinue to learn more about how enzymes
known as histone deacetylases, or HDACs,
work to silence genes. Better understand-
ing of how HDACs silence genes is partic-
ularly relevant to understanding, and per-
haps better managing, diseases character-
ized by abnormal cell growth, such as can-
cer and neurological disorders.
Chromosomes contain DNA, and this
genetic material is tightly packed into
chromatin. The smallest unit
of chromatin is the nucleo-
some, where proteins known
as histones tightly bind DNA.
All this wrapping protects
genes from being decoded and
expressed inappropriately. His-
tone acetylases switch genes on
by freeing DNA from tightly
packed chromatin. HDACs
are counterpart enzymes that
operate in reverse; they shut
off genes.
Eleven types of human
HDAC were already known to
occur in complex mixtures
with related proteins, such as
gene repressors and hormone
receptors. In the course of
deciphering the components
of one of these complexes,
Ramin Shiekhattar, an associ-
ate professor in the Gene
Expression Program at the
University of Pennsylvania’s
Wistar Institute, discovered an
entirely new family of com-
plexes containing HDACs. All
the members share a common
core composed of HDAC
linked to another protein called BHC110.
A variety of other proteins are attached to
this core unit, including one involved in
X-linked mental retardation and another
associated with breast cancer. These find-
ings are described in the 28 February
2003 issue of the Journal of Biological
Chemistry.
The HDAC section of the new com-
plex binds to chromatin to shut off genes,
just like all other HDACs; the challenge
lies in uncovering what the BHC110
component does. Scientists have identi-
fied enzymes that acetylate, deacetylate,
phosphorylate, dephosphorylate, and
methylate histones. “What’s missing is an
enzyme that demethylates histones,” says
Shiekhattar. He speculates that histone
demethylation may actually be the role
played by BHC110. If this is indeed the
case, “BHC110 is going to be a hot pro-
tein,” says Shiekhattar. 
Another mystery is why diverse pro-
teins are attached to the HDAC/BHC110
core, in contrast to the other HDACs,
which bind only one type of protein to
their cores. Shiekhattar suspects that the
different proteins direct the complex to
specific tissues. For instance, one member
of the new family contains the ZNF217
gene that is amplified in breast cancer. The
HDAC/BHC110 complex with this par-
ticular subunit attached may be involved
in the regulation of breast cancer. “My gut
feeling is that we found a set of complexes
that repress different genes based on their
unique subunit,” says Shiekhattar. Experi-
ments are currently under way to explore
this theory. 
Shiekhattar’s findings add to “the col-
lective work of other laboratories that
study HDAC to impact our understand-
ing of diseases,” says Danny Reinberg, an
investigator at the Howard Hughes
Medical Institute and a distinguished
professor of biochemistry at the Univ-
ersity of Medicine and Dentistry of New
Jersey–Robert Wood Johnson Medical
School in Piscataway. The overall goal of
HDAC research is to learn how HDAC
complexes control cellular functions,
then identify compounds to block unde-
sirable actions. 
For example, defects in the acetyla-
tion/deacetylation machinery occur in
tumors and in Huntington disease. Scien-
tists at the Memorial Sloan-Kettering
Cancer Center (MSKCC) in New York
City, led by MSKCC president emeritus
Paul Marks, have discovered that the
HDAC inhibitor suberoylani-
lide hydroxamic acid (SAHA)
causes cancer cells to stop
growing and die. Their find-
ings are published in the 15
May 2003 issue of Blood.
SAHA, which was first syn-
thesized 15 years ago by
MSKCC researchers to con-
trol the cell cycle, is undergo-
ing clinical trials in cancer
patients, who show early pos-
itive outcomes. By inhibiting
HDAC, SAHA increases the
level of histone acetylation,
resulting in increased expres-
sion of genes and proteins
(such as p27kipl and gelsolin)
that are directly implicated in
tumor suppression.
SAHA has also been
shown to prevent movement
disorders in a mouse version
of Huntington disease, where
the buildup of abnormal pro-
teins in brain cells jams the
acetylation–deacetylation reg-
ulatory system. A team from
King’s College London pub-
lished findings in the 18
February 2003 issue of Proceedings of the
National Academy of Sciences that mice
with the disease that had drunk water
laced with SAHA showed significantly
less loss of movement than those that
drank plain water. 
“In years to come, we will learn that
other diseases are affected by HDAC,”
predicts Reinberg. It all goes to show that,
as Shiekhattar puts it, gene regulation is
“like driving a car”—safe driving relies as
much on braking as on accelerating.
–Carol Potera
P
h
o
t
o
d
i
s
c
INNOVATIVE TECHNOLOGIES
Hope may come from HDAcs. More information on how histone deacetyl-
ase (HDAC) compounds control cellular function could eventually lead to
treatment for conditions such as Huntington disease.Forum
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The U.S. Food and Drug Administration
(FDA) is looking at how microarray and
toxicogenomics data may be incorporated
into its drug review process. Field insiders
expect microarray data will eventually be a
standard component of submissions for
both investigational new drug appli-
cations (for use in clinical tests) and
new drug applications (for marketing
new drugs in the United States).
However, in the short run, the FDA’s
capacity to manage a deluge of these
additional data is limited. And key
questions remain as to exactly how
and when the FDA will accept
microarray data. 
Only about 1 out of every 10
drugs makes it to the first phase of
clinical trials, according to industry
estimates. Current estimates of the
cost to develop a drug run $800 mil-
lion. Experts contend that if the use
of microarray data could even double
the efficiency of drug development—
for example, by increasing the num-
ber of drug candidates that make it to
clinical trials—the savings would be
substantial. And the potential to
increase the efficiency is greater than
that, says Leslie Browne, chief operat-
ing officer of Iconix Pharmaceuticals,
based in Mountain View, California.
Microarray data could also
improve drug quality. Research has
shown that gene expression data can
catch changes early on that tradition-
ally are seen only in pathology. “A tool like
this provides an opportunity to weed out
compounds early that will have problems,”
explains Browne. In a rat study, for example,
lesions were caught at day 5 compared to
day 28 for classical histologic methods.
Other retrospective studies have demon-
strated the strength of the microarray as a
predictive tool across species.
The FDA released draft guidance on
pharmacogenomics data submissions in
November 2003. “The draft guidance is a
great start to this process, and the developing
debate will enhance the field,” says Browne.
By embracing the technology early on, “the
FDA in this case has been helping to push
this forward,” he says.
Norris Alderson, the FDA senior associ-
ate commissioner for science, intends to
develop one set of standards for use through-
out the agency, including all FDA centers.
“We’re striving to achieve—as much as pos-
sible—harmony within the agency as we
move forward to apply genomics in a regula-
tory setting,” explains John Leighton, super-
visory pharmacologist in the FDA Division
of Oncology Drug Products. “Our thinking
is evolving as we see more and more submis-
sions containing genomic data and gain a
better understanding of what is useful and
what isn’t from a regulatory standpoint.”
To help develop the guidance and learn
how to address microarray data, the FDA
Office of Testing and Research has launched
two gene expression database projects. The
first, a collaboration with Iconix, will famil-
iarize FDA reviewers with microarray basics
using Iconix’s DrugMatrix toxicogenomics
database. So far, DrugMatrix contains find-
ings on 600 compounds at multiple dosage
amounts and times. Gene expression data
are linked to information on pharmacology,
histopathology, clinical chemistry, and toxi-
cology, providing a reference for FDA
reviewers to compare findings with known
results. Iconix is also training FDA reviewers
on quality control for microarray data gen-
eration, as well as how to analyze data across
multiple microarray product platforms and
validate biomarkers from integrated
chemogenic data sets.
The second project, in partnership with
Schering-Plough and Affymetrix services
provider Expression Analysis, based in
Durham, North Carolina, is building a
database for mock gene expression data sub-
missions. According to the 23 June 2003
edition of the online news source Bioinform,
the planned internal gene expression data-
base will help educate FDA reviewers about
the format, content, and context of
microarray data submissions. 
Most experts agree that the FDA has
been legitimately conservative in its use of
toxicogenomics data so far, because there are
real risks in adapting microarrays and similar
technologies before they are mature.
“The idiosyncratic response of indi-
viduals to drugs is still quite
unknown, and just because we could
measure forty thousand genes at a
time doesn’t make this problem any
easier to solve,” says Atul Butte, a
physician and instructor of endocrin-
ology and informatics at Children’s
Hospital Boston and Harvard Med-
ical School.
Initially, Leighton sees microar-
ray technology as an adjunct to tradi-
tional drug evaluation tools that will
help researchers better understand
the underlying mechanisms of toxic-
ity, especially for long-term studies.
Moreover, he believes such data will
play a greater role, at least initially, as
a tool for enhancing an understand-
ing of a compound’s pharmacology
rather than its toxicologic properties. 
But much work needs to be done
before the FDA can determine how
microarray data should be used in
regulation, and standards need to be
established before the agency can
decide how to use such information
in risk assessment. For example, there
are no known valid biomarkers to
date, as called for in the guidance. Among
other technical challenges, a process needs to
be established for how a biomarker progress-
es from “experimental” to “probable” status,
and then to being a known biomarker. The
FDA and many other research groups are
striving to correlate content and format of
gene expression microarray data with stan-
dard toxicology and pharmacology data.
Industry in general has been slower than
the FDA to promote the use of microarrays
in the development of new drugs. “Drug
companies have been reluctant to embrace it
because they have realized the disadvan-
tages,” Browne says. But the FDA is working
to demonstrate that voluntary submission
won’t come with penalties. “We hope to
overcome the fear by some in industry that
the agency won’t know how to use the data
or make inappropriate use of the data,”
Leighton says. –Julie Wakefield
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Sequencing a Zoo
Recent comparative sequencing and analysis
of 10 genes in 13 vertebrate species has
found hundreds of identical and potentially
functional sequences in stretches of the
genome that scientists once referred to as
“junk” DNA. A recent report claims that
these sequences have been conserved
through hundreds of millions of years of
evolution, a fact that suggests they may per-
form important roles and are worthy of
future study. 
“This kind of focused compari-
son of a few genes across multiple
species can filter down the vast three
billion letters of the human genome
to a more manageable set that can
be explored for function,” says
report coauthor Eric D. Green, who
is scientific director of the Division
of Intramural Research at the Nat-
ional Human Genome Research Institute
(NHGRI).
Most genetic research has focused on
exons, sequences making up about 2% of
the total human genome that
code for the creation of pro-
teins. Until recently, it was
believed that only exonic
sequences were functional,
and that the rest of the DNA
was a sort of genetic detritus,
consisting of useless code such
as defective copies of genes,
nonsensical repeats, and the
remains of disabled retroviruses (potent
viruses such as HIV that can insinuate their
code into the DNA of their hosts). Yet there
is increasing evidence that certain sequences
outside exons that make up another 2–3%
of the human genome also play critical
roles. However, finding these nonexonic
sequences has been difficult, in part because
many are smaller than exons and lack the
“start” and “stop” signals that mark protein-
coding regions. 
In  the report, published in the 14
August 2003 issue of Nature, the team
describes sequencing the genomic region
corresponding to a section on human chro-
mosome 7 that contains 10 genes. The 10
genes were sequenced in the human and 12
other species: chimpanzee, baboon, cat, dog,
cow, pig, rat, mouse, chicken, zebrafish, and
two species of pufferfish. The sequences
were then compared using two different sta-
tistical methods in a hunt for “multispecies
conserved sequences,” or MCSs. 
A total of 1,194 MCSs were identified
between the two techniques. Of these, the
vast majority were nonexonic—only 244
overlapped exons. A little over half (648)
were  found in introns, sequences that are
transcribed to messenger RNA but removed
before the RNA is transcribed into proteins.
The rest of the MCSs (302) were found in
areas between genes. The nonexonic
sequences may possibly regulate protein
transcription or perform other functions.
Comparing two species usually isn’t
enough to find these conserved sequences,
says Green. “For example, if you take the
human genome and mouse genome, at forty
percent of the places, the DNA is so similar
that the sequences
act like Velcro—
they stick together, or align.” The vast
majority of these sequences are identical
only because the two species had a common
ancestor not all that long ago in evolutionary
terms, and there hasn’t been enough time for
any nonfunctional sequences to diverge
from each other. To find the small stretches
of sequences that are critical to gene and
organism function, it’s necessary to compare
multiple genomes, says Green.
“This work has had two immediate con-
sequences,” says Maynard V. Olson, director
of the University of Washington Human
Genome Center. “First, bioinformaticians
are using these data extensively to fine-tune
their methods for finding conserved
sequences. The second immediate conse-
quence is that this work is already guiding
choices for whole-genome [sequencing]
projects.” One of the ideas of sequencing
this whole “zoo,” says Green, is to get a bet-
ter idea of which genomes would be most
cost-effective to sequence completely in
terms of sorting out critical areas and look-
ing for elements such as MCSs. 
NHGRI researchers are continuing
their analyses to determine which genome
comparisons are most effective at finding
conserved sequences, and how many com-
parisons are necessary to find the largest
possible number of MCSs. For example, the
team found that eliminating chimpanzee
and baboon sequences from their 13-species
analysis didn’t reduce the number of MCSs
found, but removing the nonmammals
reduced the total by 17%. Their methods
are described in a paper by Green and col-
leagues published in the December 2003
issue of Genome Research.
The Nature study may be of special
interest to researchers studying cystic
fibrosis, because one of the genes analyzed
is mutated in people with that disease.
“Having the data from so many species
would certainly aid in the construction of
animal models,” says Christopher Pen-
land, director of research for the Cystic
Fibrosis Foundation. The results
could also be useful in studies of
gene therapy, in which viruses are
engineered to transport potential-
ly therapeutic genes. “You could
use this research to look for
regions in and around the gene
that nature has deemed valuable
and omit other areas to reduce the
overall load to be carried by the
virus, when the virus capacity is limited,”
says Penland. 
Olson says such multispecies sequencing
projects may also help develop better tools to
analyze single-nucleotide polymorphisms, or
SNPs, in humans—in effect, comparing
numerous humans as opposed to numerous
species. “A major issue in human genetics
right now is to improve our ability to look at
very large SNP databases and develop better
quantitative models for determining which
ones might affect function, as opposed to
being background noise,” he says.
The study also addresses a controversy
in evolutionary genetics regarding the pace
of genetic mutation. A theory called the
“molecular clock” states that mutations
occur at a steady pace across time, regardless
of species. However, the NHGRI studies
indicate that the genomes of rodents are
mutating faster than those of primates, car-
nivores, or artiodactyls (a type of ungulate).
The NHGRI study also confirms previous
work indicating that primates are more
closely related to rodents than they are to
carnivores (such as cats and dogs) or to the
hoofed artiodactyls (such as cows and pigs).
–Kris Freeman
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RNAi@elegansNet txgnet
Caenorhabditis elegans was the first multicel-
lular organism to be completely sequenced.
With that 1998 achievement came a fresh
appreciation for this popular and valuable
research model, which has become a staple of
genomics studies. Today, researchers around
the world take advantage of the Internet to
share genomics data not just on C. elegans but
also on other organisms. Accordingly, the non-
profit elegansNet website is a hub to a uni-
verse of information not just on the titular
nematode but also on several other species, as
well as genomics-relevant technologies. 
The goal of elegansNet is to simplify navi-
gation to resources on the World Wide Web,
to enhance interaction among researchers in
molecular, cellular, systems, and organism biol-
ogy, and to promote science appreciation
among the public. The site is vast, with approx-
imately 29,000 links indexed, and it draws on
all kinds of resources, from pharmaceutical
company–produced educational materials to
peer-reviewed journals. One of the technolo-
gies highlighted by elegansNet is gene silenc-
ing through RNA interference (RNAi), through
a resource page located at http://c.elegans.
tripod.com/RNAi.htm.
Under the Hot header on the homepage,
visitors will find links to RNAi research pub-
lished in the past month. This section also
includes a history and overview of RNAi provid-
ed by biology products company Ambion,
access to Ambion’s Silencer newsletter on gene silencing research and technologies, and online news
sources related to RNAi. The Literature Searches section expands on these offerings by taking visi-
tors to the National Library of Medicine PubMed homepage and running preselected searches on
pertinent topics, including RNAi therapy, transcriptional gene silencing, and posttranscriptional
gene silencing. This gives visitors the power to access the most up-to-date citations literally at the
click of a button. Visitors are have ready access to published research on high-throughput screens
and reviews of RNAi as a gene therapy approach. Papers on these topics are available under the
High-Throughput Screens (HTS) and RNAi Therapeutic Models Reviews headers on the homepage. 
The links under the Players header take visitors to online journal articles describing key ele-
ments of the world of RNAi, including Dicer, microRNA, and short hairpin RNAs. The Animations &
Images section directs visitors to websites housing time-lapse films of C. elegans. 
The Resources & Services section lists links to a number of research centers, databases, and
search engines. For example, the RNA World Databases site of the Institut für Molekulare
Biotechnologie in Jena, Germany, provides access to a vast wealth of databases, web-based tools,
and software. The RNAi.net page lists educational, career, and business opportunities for scien-
tists. The RNAi Phenotype Search, part of the WormBase consortium of C. elegans researchers,
allows visitors to search for genes with positive or wild-type RNAi assays by any of a number of
maternal, embryonic, and/or postembryonic phenotypes. And the Harvard Medical School
Drosophila RNAi Screen Center makes available a library of double-stranded RNAs that can be
used by researchers to conduct high-throughput cell-based RNAi screens to identify genes
involved in various assays. –Susan M. Booker
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Cluster Busters
Bioinformatics experts are always working
to design better statistical algorithms to
comprehend the expression patterns of
tens of thousands of genes. Different algo-
rithms may better serve diverse scientific
goals, such as screening for potential
tumor markers or obtaining a comprehen-
sive window into the state of a cell as it
reacts to an environmental toxicant. Now,
in a new use for a preexisting methodolo-
gy, Raj Acharya and Jyotsna Kasturi, two
computer scientists at The Pennsylvania
State University, have applied a mathe-
matical approach called Kullback-Leibler
(KL) clustering to the identification of
patterns in microarray data. 
Microarrays shed light the effects of
environmental toxicants on genes by
measuring the expression of thousands of
messenger RNAs simultaneously. Micro-
array experiments generate vast amounts
of data, which bioinformatics experts
examine using statistical algorithms
designed to detect patterns. Similar genes
are sorted into groups, or clusters, that
provide insights into gene interactions
and thus help to explain underlying bio-
logical processes. 
Traditionally, mathematicians and engi-
neers have used KL methods to explore
theoretical concepts. But KL clustering has
proven to be a powerful method for look-
ing at gene expression over time in
response to drugs or environmental toxi-
cants, says Murali Ramanathan, an associ-
ate professor of pharmaceutical sciences at
the University at Buffalo–The State
University of New York, who collaborated
with the Penn State scientists in proof-of-
concept studies on the approach. 
In general, clustering procedures find
similarities among data set items that form
the basis for sorting them into a series of
groups. “Clustering is like sorting differ-
ent-color balls into bins, each containing
one color,” explains Acharya, who is direc-
tor of the Penn State Advanced Laboratory
for Information Systems and Analysis.
Each ball is sorted by how closely it match-
es the color of the other balls already
assigned to bins. The algorithm calculates
a similarity score for all pairs of genes and
assigns them to a cluster. Genes within
clusters carry out similar tasks, such as
cholesterol synthesis or wound healing.
Any genes of unknown function are “guilty
by  association”—they are suspected to
have a function similar to those of known
genes in the same cluster. 
The main aim of cluster analysis of
microarray data is to expose regulatory
networks and assign function to sequences
of no known function. So researchers
desire small numbers of clusters, each
densely packed with interrelated genes that
reflect common pathways or biological
functions. In contrast, techniques that
generate many clusters containing just one
or a few genes are undesirable. 
In a proof-of-concept experiment, the
researchers applied KL clustering to genet-
ic data from the Onto-Express database of
the Wayne State University Intelligent
Systems and Bioinformatics Laboratory.
Graduate student Kasturi had written a
computer program to test KL clustering,
which was applied to 517 genes from
human fibroblasts treated with serum, rep-
resenting 12 time points. In addition, a
larger set of 4,579 yeast genes containing
18 time points in the cell cycle was ana-
lyzed. This test run, reported in the March
2003 issue of Bioinformatics, showed that
KL clustering performed better at sorting
microarray data than the standard method
of hierarchical clustering, which uses a dif-
ferent algorithm to measure the similarity
of genes. 
For the fibroblast data, KL clustering
produced about half as many clusters as
did hierarchical clustering, and KL clusters
were densely packed with similar genes. In
contrast, many of the hierarchical clusters
contained just one or two genes. A similar
pattern emerged for the yeast data. “Using
a small and large data set shows that the
program is scalable to large sets of genes,”
says Kasturi. 
Some KL clusters were compared with
known genes from Onto-Express, which
confirmed that clusters shared similar gene
functions. For example, one cluster held
genes related to cell–cell communication,
whereas another cluster controlled cellular
development. The Penn State team’s KL
clustering program is available by request by
contacting Kasturi at jkasturi@cse.psu.edu.
Toxicologists are always searching for
better ways to extract data from high-
throughput screens, and new approaches
to mining large data sets appear regularly
in the bioinformatics literature. But Chris-
topher Bradfield, a professor of oncology
at the University of Wisconsin, Madison,
and CEO of the Madison-based toxicoge-
nomics service company Functional Bio-
sciences, points out that new algorithms
are only as good as their translation into
clearer biologic understanding. “This may
be a better mouse trap,” he says, “but the
real proof will be in how many mice it
catches.” –Carol Potera
BIOINFORMATICS
Defining clusters. Comparison of red and
green cluster plots for KL clustering (left) and
hierarchical clustering (right) shows that the
former creates fewer clusters with more
genes—an important feature if scientists are
to learn more about the function of genes
based on the company they keep.
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